China-based Innovent Biologics Inc. (HKG: 1801) announced that its Phase II study of mazdutide (IBI362/OXM3) in Chinese patients with type 2 diabetes met primary endpoints. The multi-center, randomized trial compared mazdutide with placebo and dulaglutide in patients with inadequate glucose control despite lifestyle interventions and/or stable metformin doses (NCT04965506).
Study Highlights
- Endpoints Achieved: Mazdutide demonstrated superior glucose-lowering effects compared to placebo and non-inferiority to dulaglutide.
- Patient Population: Focused on individuals with type 2 diabetes poorly managed by lifestyle changes and/or metformin.
Drug Profile
Mazdutide, licensed from Eli Lilly in 2019, is a GLP-1R/GCGR dual agonist mimicking mammalian oxyntomodulin (OXM). The long-acting peptide uses a fatty acid side chain for once-weekly dosing, improving glucose tolerance and inducing weight loss via receptor activation.-Fineline Info & Tech
